Table 4.
aHRs for the risk of CKD progression according to plasma biomarker levels by glomerular or nonglomerular disease diagnosis
| Biomarkera | KIM-1 | MCP-1 | TNFR-1 | TNFR-2 | suPAR | YKL-40 |
|---|---|---|---|---|---|---|
| Glomerular (n=195), 74 events | ||||||
| Q1 | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) |
| Q2 | 1.68 (0.41 to 6.87) | 1.45 (0.74 to 2.84) | 1.12 (0.38 to 3.31) | 1.08 (0.39 to 3.01) | 1.27 (0.57 to 2.85) | 0.55 (0.26 to 1.17) |
| Q3 | 0.68 (0.17 to 2.73) | 1.01 (0.46 to 2.23) | 4.79 (1.75 to 13.1) | 3.43 (1.37 to 8.59) | 1.29 (0.51 to 3.23) | 0.90 (0.38 to 2.12) |
| Q4 | 2.49 (0.73 to 8.49) | 0.87 (0.42 to 1.81) | 6.48 (2.11 to 19.86) | 4.60 (1.79 to 11.82) | 1.42 (0.56 to 3.6) | 1.20 (0.55 to 2.63) |
| Nonglomerular (n=456), 149 events | ||||||
| Q1 | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) |
| Q2 | 1.95 (1.06 to 3.59) | 0.86 (0.52 to 1.42) | 1.44 (0.65 to 3.22) | 0.94 (0.45 to 1.96) | 0.79 (0.41 to 1.52) | 1.17 (0.58 to 2.38) |
| Q3 | 1.96 (1.09 to 3.53) | 0.88 (0.54 to 1.43) | 1.92 (0.89 to 4.15) | 1.37 (0.69 to 2.69) | 1.22 (0.65 to 2.26) | 1.51 (0.75 to 3.04) |
| Q4 | 4.49 (2.43 to 8.31) | 0.72 (0.43 to 1.19) | 2.30 (0.99 to 5.36) | 1.46 (0.71 to 3.01) | 1.08 (0.56 to 2.08) | 1.73 (0.85 to 3.53) |
Data are presented as aHR (95% CI). Adjusted for age, sex, glomerular diagnosis, BMI, hypertension, proteinuria, and baseline eGFR. suPAR, soluble urokinase receptor; Q, quartile; Ref. referent.
a
The primary outcome of CKD progression is defined as a composite of 50% decline in eGFR or ESKD.